Opioid-Associated Disease Prevention and Outreach Programs - Appeals and Membership of Standing Advisory Committee
Summary
HB94 makes targeted changes to Maryland’s law governing Opioid-Associated Disease Prevention and Outreach Programs, which are authorized syringe services and related public health programs run by local health departments or community-based organizations. The bill does not change the basic purpose of these programs: they may provide outreach, education, linkage to treatment, and distribution and collection of hypodermic needles and syringes under approved procedures and protocols.
The main operational change is to the appeals process. Under prior law, an applicant denied authorization to operate a program could appeal to the Deputy Secretary for Public Health Services; HB94 instead allows the appeal to go to the Secretary of Health or the Secretary’s designee. The bill also updates the Standing Advisory Committee on Opioid-Associated Disease Prevention and Outreach Programs by replacing references to the Deputy Secretary with the Secretary or designee and preserving the committee’s role in technical assistance, recommendations, and program oversight. It also directs the Department’s regulations to reflect the revised appeals process and standard of review.
In practical terms, the bill affects the Maryland Department of Health, local health officers, local health departments, and community-based organizations seeking to establish or expand opioid disease prevention and outreach programs. It amends provisions in the Health-General Article, particularly §§ 24-902, 24-904, and 24-905, while leaving the underlying authorization framework intact. The bill takes effect July 1, 2025.
The overall sentiment around HB94 appears strongly supportive and noncontroversial. It passed the House 131-0 and the Senate 47-0, indicating unanimous approval in both chambers. The absence of recorded committee testimony in the provided materials also suggests the bill was viewed as a technical or administrative update rather than a substantive policy shift.
The main point of contention, to the extent one exists, is procedural rather than ideological: the bill centralizes appeal authority with the Secretary of Health or a designee instead of the Deputy Secretary for Public Health Services. No opposition is reflected in the voting record, and the committee structure and program requirements remain otherwise unchanged.
Impact
HB94 amends the Health-General Article to revise the administrative review process for opioid-associated disease prevention and outreach program applications and to update the composition and leadership references for the Standing Advisory Committee. It shifts appeal authority from the Deputy Secretary for Public Health Services to the Secretary of Health or the Secretary’s designee, and requires implementing regulations to conform to that change. The bill affects local health departments, community-based organizations, local health officers, and the Maryland Department of Health, but does not alter the core authorization standards or program functions.
Sentiment
The bill appears to have received unanimous and bipartisan support, passing both chambers without any recorded dissent. The votes suggest it was treated as a routine administrative or technical measure supporting existing public health and harm-reduction programs. No committee controversy is reflected in the provided materials.
Contention
There is little evidence of substantive contention in the available record. The only notable issue is the reassignment of appeal authority from the Deputy Secretary for Public Health Services to the Secretary of Health or the Secretary’s designee, along with corresponding updates to the advisory committee membership and chair designation. Because the bill passed unanimously, any disagreement appears to have been minimal or absent.